Amazing talk by Clara Steiner ❤️❤️

💫Superstar urologist Clara Steiner presents the innovative microdevice trial in progress on behalf of Wenxin (Vincent) Xu KidneyCAN #KCRS24 OncoAlert

An intratumoral micro-device releases small amounts of drugs locally to assess efficacy #KCRS24 . Up to 20 drugs can be assessed. Here we can seen what looks like an immune responsive tumor. This could be a new corridor to personalised therapy.Sumanta K. Pal, MD, FASCO looking on with enthusiasm

The #INTerpath-004 trial explores the combination of pembro + personalized mRNA #vaccine for the adjuvant treatment of pts with RCC. Inspiring talk by Toni Choueiri, MD at #KCRS24! KidneyCAN Dana-Farber Lank Center for Genitourinary Oncology OncLive.com

Congrats Emre Yekedüz et al. Applying Genomic Analysis to Refine Unclassified Renal Cell Carcinoma (uRCC) Dana-Farber Dana-Farber Lank Center for Genitourinary Oncology Ankara Üniversitesi Kidney Cancer Toni Choueiri, MD Neeraj Agarwal, MD, FASCO Sumanta K. Pal, MD, FASCO Nazli Dizman Bryan Lewis Hans Hammers Rana McKay, MD, FASCO Fabio Schutz Laurence Albiges

Giants on stage discussing the latest updates in clinical trials in mRCC. #KCRS24 Toni Choueiri, MD David Braun Rana McKay, MD, FASCO Laurence Albiges Bradley McGregor Tom Powles Robert Motzer MD

Pretty cool when your Doctor & Friends present latest updates in Kidney Cancer. Accelerating Cures & Providing Hope. Thank you KidneyCAN . Let’s go!! ☘️ Toni Choueiri, MD Dana-Farber Lank Center for Genitourinary Oncology Michael Serzan, MD Dana-Farber The Jimmy Fund

Literally everyone's favorite physicians/researchers/speakers to learn from All ⭐️⭐️⭐️⭐️⭐️⭐️⭐️ panel bringing us all the updates in the field! #KCRS24 KidneyCAN

🚨Oral abstract session: brilliant postdoc fellows Karl Semaan, MD, MSc and Eddy Saad casually sitting and presenting next to giants in the field!⭐️ IM residency program, take notes: they are applying this cycle! #KCRS24 OncoAlert KidneyCAN

Our ⁦Dana-Farber Lank Center for Genitourinary Oncology⁩ ⁦Karl Semaan, MD, MSc⁩ and ⁦Eddy Saad⁩ presenting #KCRS24 ably mentored by ⁦Sylvan Baca MD PhD (Hiring!)⁩ and ⁦Sasha Gusev⁩ ⁦Dana-Farber⁩ ⁦Harvard Medical School⁩

Superstar Eddy Saad elegantly discussed his work validating the association of an IL7 SNP with irAEs from two phase III trials at #KCRS24! 🌟 Toni Choueiri, MD Sasha Gusev Eli Van Allen Dana-Farber Lank Center for Genitourinary Oncology OncoAlert KidneyCAN

Dr. Eddy Saad presented an analysis of IL7 SNP predicting for immune related AEs. Very interesting and important data showing that IL7 SNP patients may be at an increased risk of irAEs, and no association to outcome. #KCRS24

Thank you to Clara Steiner, of Dana-Farber, for stopping by during #KCRS24 to talk about a pilot study of an implantable microdevice for the in vivo evaluation of drug response in RCC! See our site for more from the conference! #kcsm onclive.com/conference/kid…

Now ⁦Renee Maria Saliby⁩ “RMS” discussing new endpoints from RWD in RCC from ⁦IMDC⁩ —thank you mentors ⁦Daniel Heng⁩ ⁦David Braun⁩ #KCRS24 #WCRM ⁦KidneyCAN⁩

🔝 Renee Maria Saliby rocks the stage discussing intermediate endpoints for efficacy of ICI-based regimens from IMDC RWD! #KCRS24 Toni Choueiri, MD Daniel Heng David Braun Dana-Farber Lank Center for Genitourinary Oncology Yale Internal Medicine OncoAlert

⭐️Renee Maria Saliby presenting her work on intermediate endpoints in RCC #KCRS24 OncoAlert KidneyCAN IMDC Always a pleasure to hear her speaking and excited to see what the future holds for her!

#TiNivo-2 results are out —adding PD1 inhibitor nivolumab simply does not help after rechallenge /progression on prior immunotherapy. Time to follow level 1 evidence! PRNEWS Targeted Oncology OncLive.com KidneyCAN Kidney Cancer Uromigos Oncology Brothers —implications beyond renal cancer ?

It was an honor to be part of my first roundtable with Tian Zhang, MD, MHS and Shahla Bari MD 👩🏽‍⚕️⭐️ 🎙️Discussing a huge clinical unmet: non-clear cell RCC Special thanks to our exceptional moderator, Laurence Albiges for guiding the discussion👑

1/ Results from #LITESPARK-005 are out NEJM! The phase 3 trial that led to HIF-2 inhibitor Belzutifan (BEL) U.S. FDA approval Dec 2023 in pretreated pts w/ #ccRCC. Presentation #ESMO24 @myEsmo Check it out: nejm.org/doi/full/10.10…

Liquid biopsy in renal cell carcinoma | The Oncologist | with Marc Machaalani Karl Semaan, MD, MSc Marc Eid Rashad Nawfal, MD Razane El Hajj Chehade Sylvan Baca MD PhD (Hiring!) from Dana-Farber Lank Center for Genitourinary Oncology academic.oup.com/oncolo/advance…